On the TRAIL to therapeutic intervention in liver disease (Q36863153)

16 August 2017

1 reference

title

On the TRAIL to therapeutic intervention in liver disease (English)

1 reference

16 August 2017

3

Markus W Büchler

1 reference

16 August 2017

Ingrid Herr

1

1 reference

PubMed ID

17596886

16 August 2017

Peter Schemmer

series ordinal

2

1 reference

PubMed ID

17596886

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

46

1 reference

16 August 2017

1

1 reference

16 August 2017

266-274

1 reference

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

16 August 2017

1 reference

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

Detection of soluble TRAIL in HBV infected patients and its clinical implications

21 January 2018

1 reference

CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.

21 January 2018

1 reference

Apoptosis and liver disease

21 January 2018

1 reference

7 January 2021

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

1 reference

7 January 2021

Apoptosis: the nexus of liver injury and fibrosis.

1 reference

7 January 2021

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

1 reference

7 January 2021

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

1 reference

7 January 2021

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

7 January 2021

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

1 reference

7 January 2021

Tumor therapeutics by design: targeting and activation of death receptors

1 reference

7 January 2021

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

7 January 2021

TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

1 reference

7 January 2021

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

1 reference

7 January 2021

Nature's TRAIL--on a path to cancer immunotherapy

1 reference

7 January 2021

Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages

1 reference

7 January 2021

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

1 reference

7 January 2021

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

1 reference

7 January 2021

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

1 reference

7 January 2021

Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice.

1 reference

7 January 2021

Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.

1 reference

7 January 2021

Apo2L/TRAIL and its death and decoy receptors

1 reference

7 January 2021

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

7 January 2021

TRAIL and apoptosis induction by TNF-family death receptors.

1 reference

7 January 2021

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

1 reference

7 January 2021

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

1 reference

7 January 2021

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

7 January 2021

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

1 reference

7 January 2021

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

1 reference

7 January 2021

Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines

1 reference

7 January 2021

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

1 reference

7 January 2021

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

7 January 2021

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

7 January 2021

TRAIL/Apo-2-ligand-induced apoptosis in human T cells.

1 reference

7 January 2021

Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

1 reference

7 January 2021

Genomic organization and transcriptional regulation of human Apo2/TRAIL gene.

1 reference

7 January 2021

Viruses and the TNF-related cytokines, an evolving battle

1 reference

7 January 2021

Reovirus-induced apoptosis is mediated by TRAIL

1 reference

7 January 2021

Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l

1 reference

7 January 2021

Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4(+) T cells

1 reference

7 January 2021

Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta

1 reference

7 January 2021

Involvement of TRAIL and its receptors in viral hepatitis

1 reference

7 January 2021

Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity

1 reference

7 January 2021

Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis

1 reference

7 January 2021

Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1.

1 reference

7 January 2021

Critical roles of TRAIL in hepatic cell death and hepatic inflammation.

1 reference

7 January 2021

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake

1 reference

7 January 2021

Following the TRAIL from hepatitis C virus and alcohol to fatty liver

1 reference

7 January 2021

1 reference

7 January 2021

Hepatic stellate cell behavior during resolution of liver injury

1 reference

7 January 2021

Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis.

1 reference

7 January 2021

Death receptors: signaling and modulation

1 reference

7 January 2021

Mitochondria and apoptosis

1 reference

7 January 2021

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

1 reference

7 January 2021

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

1 reference

7 January 2021

CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells

1 reference

7 January 2021

Cross-talk in cell death signaling

1 reference

7 January 2021

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

1 reference

7 January 2021

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

1 reference

7 January 2021

Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins.

1 reference

7 January 2021

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

1 reference

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

7 January 2021

Missing pieces in the NF-kappaB puzzle

1 reference

7 January 2021

NF-kappaB at the crossroads of life and death

1 reference

7 January 2021

A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B

1 reference

7 January 2021

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

1 reference

7 January 2021

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

7 January 2021

Proteasome inhibition induces hepatic stellate cell apoptosis

1 reference

7 January 2021

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.

1 reference

7 January 2021

Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma

1 reference

7 January 2021

The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis

1 reference

7 January 2021

Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta

1 reference

7 January 2021

Inflammation and cancer

1 reference

7 January 2021

The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis

1 reference

7 January 2021

Stromal fibroblasts in cancer initiation and progression

1 reference

7 January 2021

Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells

1 reference

7 January 2021

Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis

1 reference

7 January 2021

Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.

1 reference

7 January 2021

The role of tumor stroma in the interaction between tumor and immune system

1 reference

7 January 2021

Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors

1 reference

7 January 2021

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

1 reference

7 January 2021

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

1 reference

7 January 2021

A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance

1 reference

7 January 2021

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

1 reference

7 January 2021

Matrix metalloproteinases in tumor invasion

1 reference

7 January 2021

An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells

1 reference

7 January 2021

Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases

1 reference

7 January 2021

Death and anti-death: tumour resistance to apoptosis

1 reference

7 January 2021

Hypoxia and low glucose differentially augments TRAIL-induced apoptotic death

1 reference

7 January 2021

Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21740

1 reference

16 August 2017

1 reference

PubMed ID

17596886